“…Thirty-six studies addressed the technical value as a key element. The majority (eight studies; 22.22%) of the studies concerned influenza vaccines ( 35 , 38 , 48 – 52 , 58 ) and HPV (eight studies; 22.22%) ( 27 , 33 , 40 – 42 , 46 , 55 , 61 ), five pneumococcal vaccines (13.9%) ( 34 , 36 , 44 , 45 , 62 ), three rotavirus (8.3%) ( 39 , 47 , 59 ), while six (16.7%) multiple vaccines ( 31 , 32 , 37 , 43 , 56 , 60 ). Eventually, six (16.67%) did not address any specific vaccines in particular ( 25 , 26 , 29 , 53 , 54 , 57 ).…”